New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
HIGHER: Aeroflex (ARX), up 25% after agreeing to be acquired by Cobham for about $1.46B... Clovis (CLVS), up 6.6% after receiving breakthrough therapy designation for CO-1686... Ophthotech (OPHT), up 17.6% after entering into an ex-U.S. licensing, commercialization agreement with Novartis (NVS) for Fovista... Dendreon (DNDN), up 9% after announcing presentation of PROVENGE ProACT, IMPACT studies data... Iridium (IRDM), up 5% after upgraded at Raymond James... Acxiom (ACXM), up 3% after upgraded at Wells Fargo... Carnival (CCL), up 2% following upgrade at Morgan Stanley. DOWN AFTER EARNINGS: Dick's Sporting (DKS), down 15%. Peer Cabelas (CAB) also down 2% after Dick's report... Staples (SPLS), down 10%. Peer Office Depot (ODP) also down 2.6% after Staples' report... Urban Outfitters (URBN), down 4%... TJX (TJX), down 4.7%. ALSO LOWER: Intercept (ICPT), down 5.8% after The Street reported that the company knew of abnormal cholesterol levels in patients taking its liver disease drug obeticholic acid... Graphic Packaging (GPK), down 3% after offering 43.65M shares of common stock for holders... LiveDeal (LIVE), down 15% after entering 10M share common stock distribution agreement... Endocyte (ECYT), down 5% after company and partner Merck (MRK) withdraw CMA for vintafolide in Europe.... Molycorp (MCP), down 2.5% after downgraded at Morgan Stanley.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
October 2, 2015
13:51 EDTMRKFDA approves Merck's Keytruda for advanced non-small cell lung cancer
The U.S. Food and Drug Administration granted accelerated approval for Keytruda to treat patients with advanced non-small cell lung cancer whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors. In 2014, Keytruda was approved to treat patients with advanced melanoma following treatment with ipilimumab, a type of immunotherapy. Keytruda is marketed by Merck and the PD-L1 IHC 22C3 pharmDx diagnostic test is marketed by Dako North America.
13:43 EDTMRKFDA approves Merck lung cancer treatment Keytruda
Subscribe for More Information
11:21 EDTACXMAcxiom management to meet with Stephens
Meeting to be held in New York on October 8 hosted by Stephens.
05:44 EDTSPLS, ODPStocks with implied volatility above IV index mean; ODP SPLS
Subscribe for More Information
October 1, 2015
16:18 EDTGPKGraphic Packaging acquires assets of Carded Graphics, terms not disclosed
Graphic Packaging announced that its wholly owned subsidiary, Graphic Packaging International, has acquired the converting assets of Staunton, VA based Carded Graphics, an award winning printed folding carton producer with a strong regional position in the food, craft beer and other consumer product markets. The transaction will be funded with existing cash and borrowings from Graphic Packaging's revolving line of credit.
11:06 EDTNVSXOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading.
08:06 EDTMRKMerck, DNAtrix announce Phase 2 immuno-oncology collaboration
Subscribe for More Information
07:37 EDTNVSXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information
07:23 EDTMRKNewLink Genetics awarded $18M contract option from BARDA
NewLink Genetics Corporation (NLNK) announced today that the Biomedical Advanced Research and Development Authority, or BARDA, of the United States Department of Health and Human Services, or HHS, has exercised an $18M option on NewLink Genetics' existing contract to support the scale-up of the manufacturing process relating to its investigational rVSV-ZEBOV GP vaccine candidate. BARDA made an initial $30M contract award to NewLink in late 2014 and is now providing additional funding to continue development of the Ebola vaccine candidate. Merck (MRK) has the license for research, development, manufacturing and commercialization of the rVSV-ZEBOV GP vaccine.
07:23 EDTMRKNewLink Genetics awarded $18M contract option from BARDA
Subscribe for More Information
05:32 EDTSPLS, ODPStocks with implied volatility above IV index mean; ODP SPLS
Stocks with implied volatility above IV index mean; Office Depot (ODP)95, Staples (SPLS) 70 according to iVolatility.
05:18 EDTMRKBioMarin to host a conference call
Subscribe for More Information
September 30, 2015
17:04 EDTNVSNovartis says results of Phase 3 study of secukinumab met endpoints
Subscribe for More Information
09:19 EDTOPHTOphthotech weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
05:33 EDTODP, SPLSStocks with implied volatility above IV index mean; ODP SPLS
Stocks with implied volatility above IV index mean; Office Depot (ODP) 101, Staples (SPLS) 73 according to iVolatility.
September 29, 2015
16:03 EDTCLVSClovis announces two major regulatory milestones for rociletinib
Subscribe for More Information
12:35 EDTNVSPerrigo shareholders pressure company to explore sale, Reuters says
Certain Perrigo (PRGO) shareholders have requested that company explore a sale, hoping for an alternative to Mylan's (MYL) approximately $25B hostile bid, Reuters reports, citing people familiar with the matter. The pressure represents a challenge to Perrigo's defense strategy, the report says. Some of the company's shareholders view Novartis (NVS), Sanofi (SNY), Procter & Gamble (PG), and Colgate-Palmolive (CL) as potential suitors, the report says. Reference Link
08:46 EDTNVSNoven reports final decisions in IPRs challenging Novartis' Exelon patch patents
Subscribe for More Information
08:35 EDTCCLCarnival expands its Wi-Fi network for ships
Carnival announced that it has expanded its innovative hybrid connectivity system to create the cruise industry's largest Wi-Fi network. With over 31 advanced satellite systems, the company's expanded WiFi@Sea connectivity network features the broadest high-bandwidth internet coverage in the industry currently deployed on 30 of its 100 ships with further deployment planned over the next several months.
05:11 EDTODPStocks with implied volatility above IV index mean; ODP P
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use